Comparing GnRH Agonist Trigger and Support to Standard hCG and Progesterone in IVFICSI Cycles for Women Aged 18 to 39

What this Trial Is About

The trial investigates luteal phase support strategies in women undergoing in vitro fertilization IVF or intracytoplasmic sperm injection ICSI cycles. Researchers aim to address the paradox where obtaining a large number of oocytes improves success but increases risks like ovarian hyperstimulation syndrome OHSS and implantation failure due to altered endometrial receptivity. The study evaluates a new protocol combining GnRH agonist triggering with GnRH agonist luteal phase support compared to the standard approach using hCG triggering and vaginal progesterone support. Two treatment groups are compared one receiving hCG injection before oocyte retrieval and vaginal progesterone afterward, and the other receiving a GnRH agonist Triptorelin injection before retrieval with nasal GnRH agonist Nafarelin support during the luteal phase. Both protocols begin treatment 36 to 38 hours before oocyte retrieval and continue luteal support until the first pregnancy test. The new protocol is designed to reduce OHSS risk and improve pregnancy rates by supporting the bodys own hormone production. Participants will be closely monitored through pregnancy testing and ultrasound assessments to measure outcomes such as live birth rates, embryo implantation, clinical pregnancy, miscarriage, and pregnancy complications. Hormone levels will be tracked at oocyte retrieval and during follow-up lasting up to 19 months. Safety events including OHSS and adverse outcomes will also be recorded. Women aged 18 to 39 undergoing their first or second IVFICSI attempt are involved, with the study lasting through pregnancy and delivery outcomes.

Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF/ICSI Cycles